FDA grants breakthrough designation to Alnylam's FAP candidate

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said FDA granted breakthrough therapy designation to patisiran (ALN-TTR02) to treat familial amyloidotic polyneuropathy (FAP), a

Read the full 202 word article

User Sign In